Why Martin Shkreli Says AI Won't Discover a Drug for 10 Years
Martin Shkreli rejects claims from Dario Amodei, arguing wet labs and FDA trials will prevent AI drug discovery for a decade.
Martin Shkreli: Big Pharma's Blind Spot, Betting Against Quantum & What Prison Taught Him
With Martin Shkreli, Jason Calacanis, Brad · Sunday, October 18, 2026
Former hedge fund manager and pharmaceutical executive Martin Shkreli joins the show to discuss why he is shorting quantum computing and why he believes the technology lacks commercial viability. He details the market inefficiencies in big pharma that allowed him to acquire and repurpose blockbuster drugs, and pushes back against claims that AI will revolutionize drug discovery. Finally, Shkreli reflects on the psychology of intellectual arrogance, his interactions with figures like Sam Bankman-Fried, and the personal lessons learned while serving time in federal prison.
Key takeaways
- Dario Amodei predicts artificial intelligence will cure most human diseases in the coming years, while Martin Shkreli predicts zero clinically meaningful AI-discovered drugs will reach the market over the next decade. Read more →
- Martin Shkreli bought the rights to Sparsentan from Bristol Myers Squibb for $2 million; today, the public company holding that drug is worth $6 billion. Read more →
- Foundational intelligence will commoditize like the early internet, leaving value in the hands of consumers and operational businesses rather than raw model hosts. Read more →
- Quantum computers operate at clock speeds measured in hundreds or thousands of hertz, whereas classical silicon chips run at multiple gigahertz. Read more →
- Martin Shkreli predicts Nvidia flagships like the H100 and B200 will sit in the scrap heap within twenty years, replaced by optical architectures. Read more →
5 articles from this episode
Martin Shkreli on How to Turn Big Pharma Discards into Billions
Martin Shkreli explains how acquiring neglected molecules from Pfizer and Bristol Myers Squibb built a $6 billion company.
Meta Wins AI Distribution While Models Commoditize
Martin Shkreli explains why Meta will outlast raw model providers and why foundational AI intelligence heads toward zero margin.
Why Martin Shkreli Is Shorting Quantum Computing
Martin Shkreli explains why quantum computing cannot compete with Nvidia, citing slow clock speeds and the absence of quantum RAM.
Why Martin Shkreli Thinks Nvidia GPUs Will End Up on the Scrap Heap
Martin Shkreli explains why photonic computing and 1,000x transformer gains could derail Nvidia and the current AI hardware bubble.
More All-In Podcast episodes
- Is Claude Conscious? Pope Rejects, Model Welfare Movement, OpenAI's Math Backlash, France RiotsOct 11 · 4 articles
- Daniel Ek: Life After Spotify, Broken Healthcare Incentives, Catching Disease Early & AI's PotentialOct 4 · 5 articles
- Trump’s Super Intelligence Summit, AI Safety Accord, GDP Beats, Midterm PredictionsOct 4 · 4 articles
- Jake Paul & The Chainsmokers: Turning Fame into Funds, Jake Enters Politics? & Venture Bubble SignsOct 4 · 6 articles